"Our identification of the PERV receptor is a major step forward because it allows us to address fundamental aspects of the biology of this virus," said Dr Clive Patience, Director of the Safety Program at Immerge. "For instance, PERV has grown in only three of approximately 40 human cell lines that we and others have tested. To date, we have not understood why most human cells do not support PERV growth. We can now begin to address this type of fundamental issue."
PERV is a virus that all pigs are born with, which poses no harm to the pig itself. However, unlike other viruses, which can be eliminated either through breeding or raising pigs in a clean lab environment, multiple copies of PERV form part of the normal genomic DNA of pigs and are therefore passed from one generation to the next.
"PERV is of concern in developing xenotransplantation of porcine organs towards an accepted procedure in clinical medicine," commented Professor Robin Weiss from University College, London. "We need to understand the basic virology of PERV, and indeed other porcine microorganisms, before xenotransplantation can be considered a safe procedure."
There is a critical need to identify new sources of organs for the growing number of people needing life-saving transplants around the world. In the U.S. alone, there are more than 81,000 people on the waiting list for organs and an unknown number of additional people needing organs who did not qualify for the transplant list because of age, illness or other issues.
"There is an unmet need in clinical transplantation for donors, and the availability of acceptable porcine organs could solve this huge demand" said Professor Dan Salomon from The Scripps Research Institute. "It remains important to identify the risk of a potentially infectious agent to both the patient receiving a transplant as well as others. Our identification of the PERV receptors will allow us to begin to address this issue."
As part of its progress toward clinical xenotransplantation, Immerge BioTherapeutics Inc. has developed a safety program with a number of international expert collaborators. The depth of Immerge's safety program is unique among companies conducting xenotransplantation research. The company has previously reported the identification of animals within its miniature swine herd that do not transmit PERV to human cell lines (Oldmixon et al. Journal of Virology 2002; 76: 3045-3048). In the past year, in collaborative efforts with the University of Missouri-Columbia and Infigen, Inc., Immerge also announced the birth of cloned, double knock-out miniature swine that lack expression of the GGTA1 gene. This gene is responsible for rapid rejection of organs and makes the animal organs more compatible for potential human transplant.
Immerge BioTherapeutics was formed on September 26, 2000, as a joint venture between Novartis Pharma AG and BioTransplant Incorporated. The company, which began operations on January 2, 2001, focuses its research efforts toward developing therapeutic applications for xenotransplantation.
Journal
Proceedings of the National Academy of Sciences